PureTech Announces Annual Results for Year Ended December 31, 2020

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced its results for the year ended December 31, 2020 as well as its cash balance as of the first quarter ended March 31, 2021. The following information represents select highlights from the full report, which will be filed as an Exhibit to Form 20-F with the United States Securities and Exchange Commission and is also available at

Puretech Health

NASDAQ:PRTC

PRTC Rankings

N/A Ranked by Market Cap

N/A Ranked by Dividends

PRTC Latest News

May 9, 2025

PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)

May 1, 2025

PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference

Apr 30, 2025

PureTech Announces Annual Results for Year Ended December 31, 2024

Apr 23, 2025

PureTech Health: Notice of Results

Apr 9, 2025

PureTech Appoints Peel Hunt as Joint UK Corporate Broker

PRTC Stock Data

Market Cap 421.53M

Float 24.02M

Institutions Ownership 1.56%

Short Percent 0.09%

Industry Biotechnology

Sector Healthcare

Website Link

Country United States

City Boston